SynthesisBMC cancer2025

Comparative efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy in HR+/HR2- patients with advanced or metastatic breast cancer: a systematic review and network meta-analysis.

Yuan Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.